We only have this paper's title and publication details.
Read it at the sourceCaptured external expert commentary on this paper, strongest first. Original sources are linked where available.
“I think the relatively wide noninferiority margins and the higher stroke finding – albeit with a lower bleeding risk – gave some people pause about the idea of doing LAAO in just about anyone with AFib. The standard indication though, thinking about this for people who've had some problems with anticoagulation, makes a lot of sense.”
“The CLOSURE-AF study raises the burden of proof to demonstrate at worst equivalence, if not superiority, of the device, and I don't think that CHAMPION-AF convincingly provided that proof.”
“The CHAMPION-AF trial showed a slightly higher event rate for ischemic stroke compared with direct oral anticoagulants (DOACs), and this signal was most apparent in the over-75 age group.”
No takes yet. Share an insight, caveat, or question.
Ömerovic et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: